secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K/A
Filed at:   2023-03-21T23:59:59+00:00
Accession:  0001193125-23-075736
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enliven Therapeutics files audited FY2022 financials with net loss of $37.7M; pro forma cash from $164.5M financing
--------------------------------------------------------------------------------

- Net loss of $37.7M for year ended Dec 31, 2022 vs $24.7M in 2021; R&D spend rose 51% to $31.0M.
- Cash and equivalents of $75.5M at Dec 31, 2022; $164.5M PIPE closed concurrently with merger on Feb 23, 2023.
- Pro forma financials reflect reverse recapitalization with Imara Inc.; Enliven is accounting acquirer.
- Accumulated deficit of $82.9M; company expects current cash to fund ops for at least 12 months.
- Audited balance sheet shows total assets of $83.3M and total liabilities of $10.4M at Dec 31, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312523075736/0001193125-23-075736-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312523075736/d415677d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-075736

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer